Join
Live feed
·
PRReleasevia Quantisnow
Sierra Oncology Inc. logo

Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

ByQuantisnow·Wall Street's wire, on your screen.
SRRA· Sierra Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SRRA (Sierra Oncology Inc.) and more on Quantisnow.